SavedAdd your journal

Journals / Erciyes Medical Journal / 2022 / Cilt: 44 - Sayı: 1

Serum Adropin: Pathogenesis and Clinical Research in Cardiovascular Disease

Lütfü AŞKIN
Okan TANRIVERDİ
Yusuf HOŞOĞLU
Hüsna Şengül AŞKIN
Pages
8–11
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The objective of this review was to contribute to the literature by examining research of the expression, processing, biological function, and role of adropin in the prevention of CVD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Adropin is a peptide hormone that acts as a stabilizing factor in body energy metabolism and may be a marker for cardiovascular disease (CVD).
📊
Key Findings & Data:The serum adropin level has been shown to be positively correlated with the nitrite/nitrate level and adropin appears to provide a protective endothelial function.
💡
Conclusion & Impact:The objective of this review was to contribute to the literature by examining research of the expression, processing, biological function, and role of adropin in the prevention of CVD.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Adropin is a peptide hormone that acts as a stabilizing factor in body energy metabolism and may be a marker for cardiovascular disease (CVD). The serum adropin level has been shown to be positively correlated with the nitrite/nitrate level and adropin appears to provide a protective endothelial function. Adropin has been reported to play a protective role in heart failure and hypertension. The underlying mechanism may help to reduce obesity and insulin resistance, improve endothelial dysfunction, and modulate the activity of the nervous system. Adropin regulates the cardiac energy cycle through a series of reactions, such as insulin signaling, glucose, and fat oxidation. This regulation of the energy circuit may represent a source of an alternative therapy for obese diabetes. The objective of this review was to contribute to the literature by examining research of the expression, processing, biological function, and role of adropin in the prevention of CVD.

🔖

Cite This Article

AŞKIN, L., TANRIVERDİ, O., HOŞOĞLU, Y., AŞKIN, H. Ş. (2022). Serum Adropin: Pathogenesis and Clinical Research in Cardiovascular Disease. Erciyes Medical Journal, Cilt: 44 - Sayı: 1, 8–11. https://ajindex.com/articles/502096

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kolben Y, Weksler-Zangen S, Ilan Y. Adropin as a potential mediator of the metabolic system-autonomic nervous system-chronobiology axis: Implementing a personalized signature-based platform for chronotherapy. Obes Rev 2021; 22(2): e13108
  2. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al. Adropin is a novel regulator of endothelial function. Circulation 2010; 122(11 Suppl): S185–92
  3. Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring) 2012; 20(7): 1394–402
  4. Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, et al. Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther 2013; 31(3): 174–8
  5. Jones E, Eteiba W, Merz NB. Cardiac syndrome X and microvascular coronary dysfunction. Trends Cardiovasc Med 2012; 22(6): 161–8
  6. Demircelik B, Cakmak M, Nazli Y, Gurel OM, Akkaya N, Cetin M, et al. Adropin: a new marker for predicting late saphenous vein graft disease after coronary artery bypass grafting. Clin Invest Med 2014; 37(5): E338–44
  7. Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and nondiabetic patients. Clin Chem Lab Med 2014; 52(5): 751–8
  8. Niepolski L, Grzegorzewska AE. Salusins and adropin: New peptides potentially involved in lipid metabolism and atherosclerosis. Adv Med Sci 2016; 61(2): 282–7
  9. Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med 2013; 61(8): 1161–4
  10. Yu HY, Zhao P, Wu MC, Liu J, Yin W. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept 2014; 190-1: 46–9
  11. Raposeiras Roubín S, Barreiro Pardal C, Roubín-Camiña F, Ocaranza Sanchez R, Alvarez Castro E, Paradela Dobarro B, et al. High-sensitivity C-reactive protein predicts adverse outcomes after non-ST-segment elevation acute coronary syndrome regardless of GRACE risk score, but not after ST-segment elevation myocardial infarction. Rev Port Cardiol 2013; 32(2): 117–22
  12. Zhao LP, Xu WT, Wang L, You T, Chan SP, Zhao X, et al. Serum adropin level in patients with stable coronary artery disease. Heart Lung Circ 2015; 24(10): 975–9
  13. Gu X, Li H, Zhu X, Gu H, Chen J, Wang L, et al. Inverse correlation between plasm